Nature Headline! China’s CAR-T Therapy Breakthrough Leads the World—A New Hope for Autoimmune Disease Treatment  

🌟 **Nature Headline!** China’s CAR-T Therapy Breakthrough Leads the World—A New Hope for Autoimmune Disease Treatment

Autoimmune

#CAR_Therapy #CRISPR #AutoimmuneDisease #Immunotherapy #Nature #Autoimmune #IMNM #dcSSc #immunemediatednecrotizingmyopathy #cutaneoussystemicsclerosis

💪 Chinese medical scientists have made a major breakthrough in treating autoimmune diseases with revolutionary CAR-T therapy. This study, conducted by scientists from three Chinese universities, was published in the prestigious journal *Cell* on October 04, 2024. It is the first study to use universal CAR-T cells derived from healthy donors, successfully helping three autoimmune disease patients achieve long-term remission. This marks a new era in treating difficult-to-treat autoimmune diseases globally.

📈 Traditional CAR-T therapies are primarily used to treat cancer, relying on extracting immune cells from patients, modifying them genetically, and reinfusing them—an expensive and complex process. However, the Chinese research team developed a next-generation CAR-T therapy that uses gene-editing technology to modify donor-derived T cells. These cells can be mass-produced and are ready for immediate use. This new approach not only significantly reduces treatment costs but also shortens the preparation time.

In this study, three patients with severe autoimmune diseases received the universal CAR-T therapy, including a 57-year-old male patient, Mr. Gong, who suffered from systemic sclerosis. Just three days after treatment, his skin showed noticeable improvement, and he regained movement in his fingers. Two weeks later, he returned to work. Now, over a year of follow-up later, Mr. Gong’s condition remains stable, and he says he “feels great.” This demonstrates the therapy’s potential for long-term effectiveness and safety.

The development of this next-generation CAR-T therapy uses CRISPR-Cas9 gene-editing technology, allowing the modified cells to target and eliminate B cells—critical players in various autoimmune diseases. After treatment, the diseased B cells disappeared from patients, and healthy B cells regenerated, all without the occurrence of common severe side effects like cytokine release syndrome.

This achievement not only brings new hope for autoimmune disease treatment but also paves the way for future applications of CAR-T cell therapy. As clinical trials continue, more patients are expected to benefit from this groundbreaking treatment.

🎉🎉To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CAR_Therapy #GeneEditing #CRISPR #MedicalBreakthrough #AutoimmuneDisease #Immunotherapy #StemCellResearch #CellTherapy #Biotech #FutureOfMedicine #MedicalInnovation #HealthRevolution #ChineseScience #CancerResearch #MedicalTechnology #PrecisionMedicine #GlobalHealth #ScienceNews #HealthInnovation #CureForAll

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

10 months ago CAR-T

Miracle Unfolds: Zhejiang University Hospital’s Custom CRISPR/Cas9 Gene Editing + CAR-T Cell Therapy Rebirths Patients

🌟 Miracle Unfolds: Zhejiang University Hospital’s Custom CRISPR/Cas9 Gene Editing + CAR-T Cell Therapy Rebirths Patients 🌟

 

👨‍👧‍👦 (“I want to live to see my child go to university!”)👨‍👧‍👦

CAR-T Cell Therapy Patient

 

🎓 This heartfelt cry came from Mr. Sun, a 40-year-old patient from Guangzhou, who faced the formidable challenge of diffuse large B-cell lymphoma, a common adult lymphoma type.

 

🔬14 rounds of chemotherapy, 20 rounds of radiotherapy, total gastrectomy… For two years,

Mr. Sun sought treatment nationwide, endured endless suffering, yet couldn’t defeat the chameleon of the tumor world – diffuse large B-cell lymphoma.

“It’s tough. Prepare yourself mentally.” “I want to live to see my child go to university.”

 

🍋Seeking a glimmer of hope, he turned to Zhejiang University Hospital in Hangzhou. This time, the doctors said, “Let’s give it a try together.”

Multiple abdominal lymphoma lesions invading the intestinal wall, multiple rounds of chemo couldn’t stop the lymphoma from spreading everywhere. Intestinal wall invasion by lymphoma is a relative contraindication for CAR-T therapy, as it can lead to intestinal perforation, so he was no longer suitable for traditional CAR-T cell therapy.

 

🌿Prof. Liu Mingyao’s team and Prof. Huang He’s team used the Nobel Prize-winning CRISPR/Cas9 gene editing technology to precisely knock out the PD1 site in T lymphocytes and insert the targeted CD19 CAR molecule for tumor cells, creating a brand-new non-viral targeted integrated CAR-T cell (PD1-19bbz), and successfully completed Phase I clinical trials in humans for the first time, verifying the safety and efficacy of the new CAR-T cells.

 

💪The brand-new PD1-19bbz CAR-T cells, with a low risk of cytokine storms and other complications, gave Mr. Sun a new lease on life.

 

👑Mr. Sun received PD1-19bbz CAR-T cell infusion and returned. Fourteen days after CAR-T cell return, all indicators were normal. After evaluation, he was discharged. One month after the return, PET-CT evaluation showed that the large mass of tumor invading the intestinal mucosa in the original abdominal cavity had completely disappeared.

 

🏸Today, Mr. Sun has been disease-free for over 2 years.

In a recent follow-up, all of Sun’s examination results were normal, his weight had increased significantly compared to before his illness, and his complexion looked much healthier. “After cell therapy, my body suddenly felt normal again. My friends and family all say I’ve miraculously recovered. Now in my spare time, I even play badminton, completely restoring my pre-illness lifestyle.”

 

Tsinghua University

🎨Two years later, in the summer of 2022, Mr. Sun shared good news with the medical staff in Hangzhou: his child has been accepted to the School of Arts at Tsinghua University!

 

🎉To assess whether the condition is suitable for CAR-T therapy, you can submit Advanced Medicine in China for preliminary evaluation!

 

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

 

🌿 #MiracleRebirth #CRISPR #CARTCellTherapy #ZhejiangUniversity #TsinghuaUniversity #MedicalBreakthroughs #CancerTreatment